As gefitinib is a selective chemotherapeutic agent, its tolerability profile is better than previous [[cytotoxic]] agents. [[Adverse drug reaction]]s (ADRs) are acceptable for a potentially fatal disease.

 


 
[[Acne vulgaris|Acne]]-like rash is reported very commonly. Other common adverse effects (≥1% of patients) include: [[diarrhoea]], nausea, [[vomiting]], [[anorexia (symptom)|anorexia]], [[stomatitis]], [[dehydration]], skin reactions, [[paronychia]], asymptomatic elevations of [[liver enzyme]]s, [[asthenia]], [[conjunctivitis]], [[blepharitis]].<ref name="AMH2004">Rossi S, editor. [[Australian Medicines Handbook]] 2004. Adelaide: Australian Medicines Handbook; 2004. {{ISBN|0-9578521-4-2}}.</ref>

 


 
Infrequent adverse effects (0.1–1% of patients) include: [[interstitial lung disease]], [[cornea]]l erosion, aberrant eyelash and hair growth.<ref name="AMH2004" />

 

